MX2008006476A - Composiciones de lipopeptidos. - Google Patents

Composiciones de lipopeptidos.

Info

Publication number
MX2008006476A
MX2008006476A MX2008006476A MX2008006476A MX2008006476A MX 2008006476 A MX2008006476 A MX 2008006476A MX 2008006476 A MX2008006476 A MX 2008006476A MX 2008006476 A MX2008006476 A MX 2008006476A MX 2008006476 A MX2008006476 A MX 2008006476A
Authority
MX
Mexico
Prior art keywords
lipopeptide
lipopeptide compositions
compositions
cyclodextrin
pharmaceutical composition
Prior art date
Application number
MX2008006476A
Other languages
English (en)
Inventor
Harald Labischinski
Stefan Pelzer
Horst Priefert
Andreas Vente
Sven-Eric Wohlert
Original Assignee
Merlion Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merlion Pharmaceuticals Gmbh filed Critical Merlion Pharmaceuticals Gmbh
Publication of MX2008006476A publication Critical patent/MX2008006476A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica que contiene como ingrediente activo un lipopéptico en dosis fisiológica eficaz, y una ciclodextrina o un derivado de ciclodextrina.
MX2008006476A 2005-11-21 2006-11-20 Composiciones de lipopeptidos. MX2008006476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005056194A DE102005056194A1 (de) 2005-11-21 2005-11-21 Neue Lipopeptid Zusammensetzungen
PCT/DE2006/002064 WO2007057005A1 (de) 2005-11-21 2006-11-20 Lipopeptid zusammensetzungen

Publications (1)

Publication Number Publication Date
MX2008006476A true MX2008006476A (es) 2008-09-26

Family

ID=37763891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008006476A MX2008006476A (es) 2005-11-21 2006-11-20 Composiciones de lipopeptidos.

Country Status (7)

Country Link
EP (1) EP1951311A1 (es)
CN (1) CN101370524A (es)
AU (1) AU2006314942A1 (es)
CA (1) CA2630497A1 (es)
DE (1) DE102005056194A1 (es)
MX (1) MX2008006476A (es)
WO (1) WO2007057005A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150218221A1 (en) * 2012-09-24 2015-08-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Method for producing a cyclic peptide
US20220218784A1 (en) * 2019-05-10 2022-07-14 Xellia Pharmaceuticals Aps Daptomycin Aqueous Formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19807972A1 (de) * 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
DE60136926D1 (de) * 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
EP1294361B1 (en) * 2000-06-21 2011-05-25 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US6699505B2 (en) * 2000-10-17 2004-03-02 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by compexing with cyclodextrins

Also Published As

Publication number Publication date
AU2006314942A1 (en) 2007-05-24
WO2007057005A1 (de) 2007-05-24
DE102005056194A1 (de) 2007-07-12
CA2630497A1 (en) 2007-05-24
EP1951311A1 (de) 2008-08-06
CN101370524A (zh) 2009-02-18

Similar Documents

Publication Publication Date Title
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
MX2010003258A (es) Utilizacion de un nuevo agente natural en composiciones cosmeticas.
MX2009005308A (es) Composiciones que comprenden peroxido de benzoilo, al menos un derivado del acido naftoico y al menos un compuesto del tipo polimeros de poliuretano o derivados de estos y sus usos.
WO2011106493A3 (en) Oral care compositions comprising magnolia bark extract or a synthetic analog thereof
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2010111640A3 (en) Anti-influenza formulations and methods
PL1965809T3 (pl) Kompozycje do poprawiania zdrowia jelit i użytkowości zwierząt zawierające beta-glukany i alfa-fukany
TW200630343A (en) 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.
MY148915A (en) An extended-release composition comprising a somatostatin derivative in microparticles
TW200640858A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
ES2325291A1 (es) "uso de un extracto de silybum marianum"
MX2008006476A (es) Composiciones de lipopeptidos.
MX2009005329A (es) Composiciones farmaceuticas anticonvulsivas.
MX2010004859A (es) Nueva composicion para tratar los efectos secundarios del tratamiento anticanceroso.
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
EP1852119A4 (en) PHARMACEUTICAL PREPARATION CONTAINING PHENOXAZINIUM DERIVATIVE AS ACTIVE INGREDIENT
MX2008002272A (es) Compuestos de ciclopropilo y composiciones para suministrar agentes activos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal